{"id":"capecitabine-aibin","safety":{"commonSideEffects":[{"rate":"60","effect":"Hand-foot skin reaction"},{"rate":"55","effect":"Diarrhea"},{"rate":"35","effect":"Nausea"},{"rate":"25","effect":"Vomiting"},{"rate":"25","effect":"Stomatitis"},{"rate":"40","effect":"Fatigue"},{"rate":"3","effect":"Neutropenia"},{"rate":"1","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL1773","moleculeType":"Small molecule","molecularWeight":"359.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Capecitabine is an oral fluoropyrimidine carbamate that undergoes hepatic and tissue-level enzymatic conversion to 5-fluorouracil (5-FU). The active 5-FU metabolite inhibits thymidylate synthase, blocking dTMP synthesis and DNA replication, while also incorporating into RNA to disrupt protein synthesis. This mechanism preferentially affects rapidly dividing cancer cells.","oneSentence":"Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:48.681Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Metastatic breast cancer"},{"name":"Gastric cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT02972372","phase":"NA","title":"Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","startDate":"2016-11","conditions":"Esophagus Cancer","enrollment":196},{"nctId":"NCT02555358","phase":"PHASE2","title":"Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Clinical Study","status":"COMPLETED","sponsor":"Qun Zhao","startDate":"2014-11","conditions":"Gastric Cancer","enrollment":300},{"nctId":"NCT02025036","phase":"PHASE3","title":"Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","startDate":"2014-10","conditions":"Stage III Esophageal Squamous Cell Carcinoma, Stage II Esophageal Squamous Cell Carcinoma","enrollment":249},{"nctId":"NCT02644408","phase":"PHASE3","title":"Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","startDate":"2014-10-01","conditions":"Stage III Esophageal Squamous Cell Carcinoma, Stage II Esophageal Squamous Cell Carcinoma","enrollment":184},{"nctId":"NCT04404491","phase":"PHASE3","title":"Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","startDate":"2020-06-01","conditions":"Esophageal Malignant Neoplasm, Local Recurrence","enrollment":240},{"nctId":"NCT03114085","phase":"PHASE2","title":"Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2017-05-20","conditions":"Hepatocellular Carcinoma","enrollment":170},{"nctId":"NCT02604615","phase":"PHASE3","title":"The Role of Different Cycles of Chemotherapy（Capecitabine-oxaliplatin） in Esophageal Chemoradiotherapy","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","startDate":"2014-10","conditions":"Stage III Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms","enrollment":60},{"nctId":"NCT02603159","phase":"PHASE3","title":"Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","startDate":"2014-10","conditions":"Stage III Esophageal Squamous Cell Carcinoma, Stage II Esophageal Squamous Cell Carcinoma","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aibin"],"phase":"phase_3","status":"active","brandName":"Capecitabine(Aibin)","genericName":"Capecitabine(Aibin)","companyName":"The First Affiliated Hospital of Henan University of Science and Technology","companyId":"the-first-affiliated-hospital-of-henan-university-of-science-and-technology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth. Used for Metastatic colorectal cancer, Metastatic breast cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}